NCT02193971View on ClinicalTrials.gov

Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)

PHASE4UnknownINTERVENTIONAL
Enrollment

3,384

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2020

Study Completion Date

June 30, 2022

Conditions
Acute Coronary Syndrome
Interventions
DEVICE

BS-DES (Biostable polymer drug-eluting stent)

DEVICE

BD-DES (Biodegradable polymer drug-eluting stent)

DRUG

Prasugrel 5mg

Use prasugrel 5mg daily for maintaning dose

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Boston Scientific Korea Co. Ltd

INDUSTRY

collaborator

Dio

INDUSTRY

collaborator

Terumo Corporation

INDUSTRY

collaborator

Abbott

INDUSTRY

lead

Seoul National University Hospital

OTHER

NCT02193971 - Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial) | Biotech Hunter | Biotech Hunter